このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

65歳以上の成人を対象としたプライマリケアにおける運動処方プログラムの有効性:PREFIS-AP

一次医療における身体運動処方プログラムの有効性:農村保健地域の65歳以上の成人の体力と生活の質を改善するためのPREFIS-AP無作為化比較試験

This randomized controlled trial aims to evaluate the effectiveness of an individualized Physical Exercise Prescription Program delivered in Primary Care for adults aged 65 years and older. The intervention includes a structured assessment of physical fitness, muscle function and mass, physical activity level, and quality of life, followed by a tailored exercise plan encompassing aerobic, strength, respiratory, flexibility, and balance training. Outcomes will be compared with a control group receiving standard health advice to walk briskly for at least 30 minutes daily. The study also explores associations between polypharmacy, muscle function, physical performance, and quality of life.

調査の概要

詳細な説明

Sedentary behavior is strongly associated with multiple adverse health outcomes, particularly in older adults. Conventional lifestyle advice alone has shown limited effectiveness in increasing physical activity levels. Exercise prescription delivered through structured evaluation, individualized planning, and scheduled follow-up may lead to clinically significant improvements in physical function and quality of life.

This study will recruit 210 adults aged ≥65 years from a rural Primary Care center. Participants will undergo baseline assessments including sociodemographic variables, anthropometric measures, muscle strength (handgrip dynamometry and chair stand test), aerobic capacity (6-minute walk test), muscle mass (calf circumference and ultrasound of rectus femoris), physical activity level (GPAQ), and quality of life (SF-36). After randomization (1:1), the intervention group will receive a personalized exercise prescription generated through the MEDORA Primary Care electronic system and supervised by a qualified Exercise Technician. The control group will receive routine health advice.

After three months, all participants will be reassessed using the same measures. The study will analyze the effect of the intervention on physical fitness, physical activity, muscle mass and function, and quality of life, including sex-specific differences and the role of polypharmacy. The project incorporates a partial masking strategy and uses REDCap for data management and anonymization.

研究の種類

介入

入学 (推定)

210

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Salamanca
      • Villoría、Salamanca、スペイン、37339
        • 募集
        • Centro de Salud de Villoria
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

65年歳以上 (高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age ≥ 65 years
  • Motivated to participate and able to provide informed consent
  • Able to attend baseline assessment and follow-up
  • Clinical stability allowing participation in exercise evaluation

Exclusion Criteria:

  • Recent myocardial infarction
  • Unstable angina
  • Uncontrolled arrhythmias (symptomatic or hemodynamically compromising)
  • Syncope
  • Acute endocarditis, myocarditis, or pericarditis
  • Severe or symptomatic aortic stenosis
  • Uncontrolled heart failure
  • Recent pulmonary thromboembolism or pulmonary infarction
  • Lower-limb thrombosis
  • Severe aortic stenosis or suspected dissecting aortic aneurysm
  • Uncontrolled asthma
  • Pulmonary edema
  • Acute respiratory failure
  • Acute non-cardiopulmonary illness that impairs exercise capacity (e.g., infection, thyrotoxicosis, acute renal failure)
  • Mental disorder that prevents adequate cooperation.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Physical Exercise Prescription Program

Participants receive a 12-week individualized multicomponent Exercise Prescription Programme integrated into routine Primary Care and supported by the MEDORA® electronic health record. Exercise prescription is based on baseline clinical and functional assessment and includes aerobic, resistance, balance and flexibility exercise, with respiratory muscle training when considered clinically indicated. Exercise is performed both independently at home and during supervised group reinforcement sessions available three days per week in municipal sports facilities. During supervised sessions, each participant follows his or her individualized exercise prescription rather than a uniform group exercise programme. Exercise type, intensity, duration, frequency and progression are individualized according to baseline clinical and functional status, tolerance and progression.

Participants receive a structured and individualized 12-week program including:

Aerobic exercise (continuous and interval training, intensity guided by Borg scale)

Strength training using elastic bands (progressively increasing repetitions, series, and load)

Respiratory exercises with pressure-based devices

Flexibility exercises (static stretching routines)

Balance training (single-leg stance, heel-toe walking, eyes-closed tasks)

The program is generated through the MEDORA electronic system after baseline evaluation. A certified Exercise Technician provides instruction, supervision, and progression adjustments.

Exercise type, intensity, duration, frequency and progression are individualized within the exercise-prescription framework according to baseline clinical and functional assessment

介入なし:Standard Health Advice

Participants allocated to the control group receive usual Primary Care and general physical-activity advice consistent with World Health Organization recommendations. They do not receive an individualized structured exercise prescription, supervised reinforcement sessions, or intervention-specific follow-up. The study did not systematically prescribe control participants to walk briskly for at least 30 minutes per day.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Quality of Life
時間枠:Baseline to 3 months.

Quality of Life will be measured by the SF-36 questionnaire. The SF-36 questionnaire is a widely used, patient-reported questionnaire measuring health-related quality of life. It uses points to assess health, with responses on Likert scales (e.g., 0 to 100) transformed into scores for 8 health domains: physical functioning, role limitations (physical/emotional), bodily pain, general health, vitality, social functioning, and mental health, where higher scores mean better health, ranging from 0 (maximum disability) to 100 (no disability).

Baseline to 3 months.

二次結果の測定

結果測定
メジャーの説明
時間枠
Physical Activity Level (GPAQ)
時間枠:Baseline to 3 months.

Change in physical activity level as measured by the Global Physical Activity Questionnaire (GPAQ), including time spent in work-related activity, transport-related activity, leisure-time activity, and sedentary behavior. Participants will be classified into WHO categories (high, moderate, or low/inactive) based on standardized scoring procedures.

Baseline to 3 months.
Aerobic Capacity (6-Minute Walk Test)
時間枠:Baseline to 3 months.

Change in functional aerobic capacity assessed by the 6-minute walk test (6MWT). The primary variable will be the total distance walked in meters during 6 minutes. Physiological responses (heart rate, oxygen saturation, perceived exertion using Borg scale) will also be recorded.

Baseline to 3 months.
Muscle Strength - Handgrip Dynamometry
時間枠:Baseline to 3 months.

Change in maximal isometric handgrip strength measured with a JAMAR dynamometer (kg), using the highest value from standardized bilateral measurements. Cut-off values will follow European sarcopenia consensus criteria (<27 kg for men; <16 kg for women).

Baseline to 3 months.
Muscle Strength - Chair Stand Test
時間枠:Baseline to 3 months.

Change in lower-limb functional strength measured by the 30-second chair stand test. The outcome is the total number of complete sit-to-stand repetitions performed within 30 seconds following standardized protocol.

Baseline to 3 months.
Muscle Mass - Calf Circumference
時間枠:Baseline to 3 months.

Change in muscle mass estimated by calf circumference (cm), measured at the widest point of the calf using a flexible tape. A value <31 cm will be considered indicative of potential muscle mass deficit.

Baseline to 3 months.
Muscle Mass - Ultrasound of Rectus Femoris
時間枠:Baseline to 3 months.

Change in quantitative and qualitative muscle parameters assessed by ultrasound of the rectus femoris (muscle thickness, cross-sectional area, and echogenicity), following validated measurement criteria for sarcopenia assessment.

Baseline to 3 months.
Sex Differences in Response to the Exercise Prescription Program (Standardized Change Score)
時間枠:Baseline to 3 months.

This outcome will assess whether biological sex modifies the effect of the intervention on functional and health-related outcomes. Sex-specific differences will be evaluated using standardized change scores (z-scores).

The standardized composite score will be derived from the following previously defined outcome measures:

Muscle strength (handgrip dynamometry (kg) and the 30-second chair stand test) Aerobic capacity (6-minute walk test) Muscle mass, assessed by calf circumference (cm) and ultrasound measurements of rectus femoris muscle thickness Physical activity level, (Global Physical Activity Questionnaire (GPAQ) Health-related quality of life (SF-36 questionnaire) Each variable will be standardized before aggregation to ensure comparability across different units of measurement. The resulting composite score will be compared between men and women to determine if sex influences the magnitude of response to the exercise prescription program.

Baseline to 3 months.
Correlation Between Polypharmacy and Change in Handgrip Strength
時間枠:Baseline to 3 months

This outcome will assess the correlation between baseline medication burden and change in muscle strength in older adults from baseline to 3 months.

Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications).

Muscle strength will be assessed by handgrip strength, measured in kilograms (kg) using a calibrated hand dynamometer. Change in handgrip strength will be calculated as the difference between baseline and 3-month values.

Baseline to 3 months
Correlation Between Polypharmacy and Change in Appendicular Skeletal Muscle Mass
時間枠:Baseline to 3 months

This outcome will assess the correlation between baseline medication burden and change in muscle mass in older adults from baseline to 3 months.

Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications).

Muscle mass will be assessed as appendicular skeletal muscle mass, measured in kilograms (kg) using dual-energy X-ray absorptiometry (DXA). Change in muscle mass will be calculated as the difference between baseline and 3-month values.

Baseline to 3 months
Correlation Between Polypharmacy and Change in Physical Performance
時間枠:Baseline to 3 months

This outcome will assess the correlation between baseline medication burden and change in physical performance in older adults from baseline to 3 months.

Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications).

Physical performance will be assessed using the Short Physical Performance Battery (SPPB), reported as a total score (points on a standardized scale). Change in SPPB score will be calculated as the difference between baseline and 3-month values.

Baseline to 3 months
Correlation Between Polypharmacy and Change in Quality of Life
時間枠:Baseline to 3 months

This outcome will assess the correlation between baseline medication burden and change in quality of life in older adults from baseline to 3 months.

Medication burden will be defined as the total number of chronic medications taken at baseline (unit: number of medications).

Quality of life will be assessed using the EuroQol-5 Dimension (EQ-5D) questionnaire, reported as a standardized index score. Change in EQ-5D score will be calculated as the difference between baseline and 3-month values.

Baseline to 3 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年2月9日

一次修了 (推定)

2026年12月1日

研究の完了 (推定)

2026年12月1日

試験登録日

最初に提出

2025年12月12日

QC基準を満たした最初の提出物

2026年2月5日

最初の投稿 (実際)

2026年2月6日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月9日

QC基準を満たした最後の更新が送信されました

2026年11月4日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

キーワード

その他の研究ID番号

  • PREFIS-AP

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Anonymized datasets and analytic code will be available upon reasonable request, following approval by the Ethics Committee and IBSAL data governance board.

IPD 共有時間枠

Data will be available starting 12 months after publication of primary results and for a minimum of 5 years thereafter.

IPD 共有アクセス基準

Qualified researchers with a methodologically sound proposal, as determined by the study steering committee, will be able to access the data. Requests should be directed to the study PI. A data access agreement will be required.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する